These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 19764041)
1. Research continues into best ways to treat low-risk prostate cancer. Printz C Cancer; 2009 Oct; 115(19):4431-2. PubMed ID: 19764041 [No Abstract] [Full Text] [Related]
2. Watching the face of Janus--active surveillance as a strategy to reduce overtreatment for localised prostate cancer. Bratt O Eur Urol; 2006 Sep; 50(3):410-2. PubMed ID: 16650924 [No Abstract] [Full Text] [Related]
3. Many unknowns in low-risk prostate cancer treatment. Ongoing studies and biomarker research may shed light on best approach. Printz C Cancer; 2009 Oct; 115(20):4645-6. PubMed ID: 19806595 [No Abstract] [Full Text] [Related]
5. Exercise therapy across the prostate cancer continuum. Antonelli J; Freedland SJ; Jones LW Prostate Cancer Prostatic Dis; 2009; 12(2):110-5. PubMed ID: 19274062 [TBL] [Abstract][Full Text] [Related]
6. Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence? Kirby RS; Fitzpatrick JM BJU Int; 2008 Dec; 102(11):1492-3. PubMed ID: 19035856 [No Abstract] [Full Text] [Related]
8. The ODAC chronicles: Part 5. Prostate cancer endpoints. Grillo-López AJ Expert Rev Anticancer Ther; 2005 Jun; 5(3):405-10. PubMed ID: 16001947 [No Abstract] [Full Text] [Related]
9. Prostate specific antigen best practice statement: 2009 update. Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717 [TBL] [Abstract][Full Text] [Related]
10. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Howard K; Barratt A; Mann GJ; Patel MI Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680 [TBL] [Abstract][Full Text] [Related]
11. Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. Zietman A J Clin Oncol; 2009 Oct; 27(30):4935-6. PubMed ID: 19720880 [No Abstract] [Full Text] [Related]
12. Cutting edge yet close to home. Cancer research in the community. Fessele KL ONS Connect; 2008 Dec; 23(12):10-4. PubMed ID: 19093339 [No Abstract] [Full Text] [Related]
13. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer; 2011 Oct; 117(20):4805; author reply 4805. PubMed ID: 21480208 [No Abstract] [Full Text] [Related]
14. Prostate cancer in the elderly. Heinzer H; Steuber T Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477 [TBL] [Abstract][Full Text] [Related]
15. United States military contributions to the National Cancer Institute. Sarvis JA; Thompson IM Urol Oncol; 2009; 27(5):558-61. PubMed ID: 19720303 [TBL] [Abstract][Full Text] [Related]
16. Clinical centers of excellence. Prostate cancer. Med Econ; 2009 Mar; 86(5):24. PubMed ID: 19351001 [No Abstract] [Full Text] [Related]
17. Open clinical uro-oncology trials in Canada. Mackenzie MJ; Rodrigues G; Winquist E Can J Urol; 2009 Jun; 16(3):4706-11. PubMed ID: 19497189 [No Abstract] [Full Text] [Related]
18. National Institute for Clinical Excellence Guideline on prostate cancer and the future of cryotherapy. Kirby R; Fitzpatrick J BJU Int; 2009 Jan; 103(2):146-7. PubMed ID: 19021627 [No Abstract] [Full Text] [Related]